// App-Quantinova.ai

273 : Objective response of the dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist, VT-464, in patients with CRPC.

Researchers

Presenter

  • Luke T. Nordquist

Principal Investigators

  • Neal D. Shore

  • Johann S. De Bono

  • Shilpa Gupta

  • William R. Berry

  • Silke Gillessen

  • Glenn Liu

  • Nicholas J. Vogelzang

  • Eleni Efstathiou

  • Mark T. Fleming

  • Daniel J. George

  • John C. Araujo

  • Jingsong Zhang

  • Michael R Kurman

  • Joel Robert Eisner

  • William R. Moore

Medical Centers

  • Urology Cancer Center and GU Research Network, Omaha, NE

  • Carolina Urologic Research Center, Myrtle Beach, SC

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • Duke University Medical Center, Durham, NC

  • Kantonsspital St Gallen, St Gallen, Switzerland

  • University of Wisconsin Comprehensive Cancer Center, Madison, WI

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Alexandra General Hospital of Athens, University of Athens, Athens, Greece

  • Virginia Onc Assoc, Hampton, VA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Moffitt Cancer Center, Tampa, FL

  • Innocrin Pharmaceuticals, Inc., Durham, NC

Locations

  • United States

  • United Kingdom

  • Switzerland

  • Greece

Companies

  • Innocrin Pharmaceuti

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Androgen Tear

  • Seviteronel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT02012920

  • NCT02361086

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved